UCL Business Ltd Analysis

Licensing UCL-developed gene therapies to pharmaceutical companies; Commercialising quantum algorithms for healthcare applications; Supporting NHS staff in launching patient-focused startups; Enabling academic researchers to develop spinout companies; Providing funding and management support for social ventures

Recognised as Best Performing New Company Creator; Portfolio includes gene therapy for rare immunological conditions; Funded Phasecraft quantum algorithm developer with $34M Series B; Supports clinical-stage therapeutic pipeline in oncology and rare diseases